Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL)
Recalled by Eugia US LLC
Class III — least serious
Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Eugia US LLC has recalled Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on June 10, 2026 and was initiated on May 18, 2026. It is classified as a Class III recall, which means using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), with approximately 168,300 vials affected. The company behind the recall is Eugia US LLC, based in East Windsor, NJ. The FDA describes the product as: “Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02”
Why was Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL) recalled?
According to the FDA, the stated reason for the recall is: “Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan.”
What should you do?
If you think you may have bought Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), compare it against the product description and identifying codes (Lot, expiry: Lot 3LC26029A, exp Feb-2029; Lot 3LC26031A, exp Mar-2029) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Eugia US LLC or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- June 10, 2026
- Recall started
- May 18, 2026
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL) recalled?+
According to the FDA: Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan
How serious is this recall?+
Class III — least serious. Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
What should I do if I have Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL)?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0552-2026. Information last synced from the FDA on July 6, 2026.